Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionBispecific human mAb with low-affinity against transferrin receptor and high-affinity against BACE1
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1) ; Transferrin receptor (TFRC) (TFR)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today